Current pharmacological treatments for retinal and choroidal neovascularization include biologic therapies targeting the vascular endothelial growth factor (VEGF) signaling pathway, but many patients experience worsened eye disease regardless of the anti-VEGF treatment. The gene discussed is VEGFA; the disease is eye disorder.